Agios Pharmaceuticals sold royalties to an approved cancer drug to get immediate cash to support its new focus on rare diseases. Earlier this year, the FDA approved the biotech’s first rare disease drug, a treatment for a type of anemia.

Leave a Reply

Your email address will not be published. Required fields are marked *